Successful Pharma-Biotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships

"The average value of pharma-biotech deals will almost treble by 2015 as pharma companies focus on gaining exclusive access to high potential technologies via large equity investments..."
In recent years, alliances between pharma and biotech companies have become increasingly common.The potential synergistic benefits to both parties have resulted in over 30% of drugs in clinical trials now being a direct product of such alliances. However, poor deal structure and implemenation continue to contribute to the failure of almost half of these relationships.

‘Successful Pharma-Biotech Alliance Strategies’ is a report published by Business Insights that provides a detailed examination of the current alliance landscape and analyses the underlying factors that can determine their success or failure. Recent major joint ventures, acquistions and licensing deals are evaluated and the latest trends and developments affecting alliance management are assessed. This report also examines 9 case studies that profile varying approaches to deal structuring and relationship management, and charts the current and future alliance activities of the top ten pharmaceutical companies. Volume and value forecasts for pharma-biotech deals to 2015 are also provided.

Explore the landscape for pharma-biotech alliances and identify the most successful approaches to deal structuring and relationship management...

Use this new report to...
• Benchmark 9 case studies of key alliance management strategies to help you optimize your drug development alliances by identifying successful and unsuccessful approaches across the areas of deal structure, relationship management and monitoring and deal renegotiation.

• Identify the factors that are pivotal to the success or failure of alliances by measuring the influence of a host of variables including management structure, therapeutic area focus, partner locations, drug development stage and manner of partner introduction.

• Assess the competitive positions of potential pharma/biotech partners with this report’s analysis of current and future biotech positions of the top ten pharmaceutical companies and a detailed evaluation of recent major joint ventures, acquistions and licensing deals.

• Understand the future landscape for pharma-biotech alliances with this report’s analysis of the latest trends and developments influencing relationship management in addition to deal trends that include volume and value forecasts for pharma-biotech deals to 2015.

Publication: 39692
Library Code: rbhc0209
Type: Report
Format: PDF
Pages: 143